CoChat
Sign Up
Cited by 416Diabetes Treatment and ManagementPharmacology and Obesity TreatmentDiabetes Management and Research

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

Open access
Blonde, L., Klein, E. J., Han, J., Zhang, B., Mac, S. M., Poon, T. H., Taylor, K. L., Trautmann, M. E., Kim, D. D., Kendall, D. M.·2006·Diabetes, Obesity and Metabolism
DOI 10.1111/j.1463-1326.2006.00602.x
Open this paper in CoChat — free accountOpen PDF

Abstract

Aim Exenatide, an incretin mimetic for the adjunct treatment of type 2 diabetes (DM2), reduced A1C and weight in 30-week placebo-controlled trials. This analysis examined the effects of exenatide on glycaemic control and weight over an 82-week period in patients with DM2 unable to achieve adequate glycaemic control with sulphonylurea (SU) and/or metformin (MET). Methods This interim analysis is of 314 patients who received exenatide in the 30-week placebo-controlled trials and subsequently in 52 weeks of open-label uncontrolled extension studies for 82 weeks of exenatide in total. Patients continued their SU and/or MET regimens throughout. Results Patients completed 82 weeks of exenatide treatment [n = 314, 63% M, age 56 +/- 10 years, weight 99 +/- 21 kg, body mass index 34 +/- 6 kg/m2, A1C 8.3 +/- 1.0% (mean +/- SD)]. Reduction in A1C from baseline to week 30 [-0.9 +/- 0.1% (mean +/- SE)] was sustained to week 82 (-1.1 +/- 0.1%), with 48% of patients achieving A1C Conclusion In summary, 82 weeks of adjunctive exenatide treatment in patients with DM2 treated with SU and/or MET resulted in sustained reduction in A1C and progressive reduction in weight, as well as improvement in some cardiovascular risk factors.

Overview

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2006.00602.x

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

Sorted by citations

See all 416

Related

See all

Metadata

Authors
Blonde, L., Klein, E. J., Han, J., Zhang, B., Mac, S. M., Poon, T. H., Taylor, K. L., Trautmann, M. E., Kim, D. D., & Kendall, D. M.
Affiliations
  • Ochsner Medical Center (US)
  • Eli Lilly (Germany) (DE)
Corresponding author
  • Mac, S. M.
  • Kim, D. D.
ORCID
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2006-04-18
Volume
8
Issue
4
Pages
436-447
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
DOI
10.1111/j.1463-1326.2006.00602.x
OpenAlex
W2093738306
Cited by
416
References
31
Citations by year
2026: 1 · 2025: 2 · 2024: 7 · 2023: 3 · 2022: 3 · 2020: 5 · 2019: 6 · 2018: 8 · 2017: 7 · 2016: 15 · 2015: 15 · 2014: 19 · 2013: 24 · 2012: 45
FWCI
38.66
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Diabetes Obesity and Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
Amylin Pharmaceuticals
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
exenatide, type 2 diabetes, incretin mimetics, HbA1c, glycemic control, weight loss, cardiovascular risk factors, sulfonylureas, metformin, adjunctive therapy, long-term treatment, nausea, hypoglycemia
MeSH terms
Exenatide, Adolescent, Adult, Aged, Blood Glucose, Blood Pressure, Body Weight, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Double-Blind Method, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Lipids, Male, Metformin, Middle Aged, Peptides, Risk Factors, Sulfonylurea Compounds, Venoms, Weight Loss, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review